Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

May 19, 2022

Study Completion Date

May 31, 2022

Conditions
Severe Hypertriglyceridemia
Interventions
DRUG

Pegozafermin

Subcutaneous injection

DRUG

Placebo

Matching placebo

Trial Locations (48)

1032

89Bio Clinical Study Site, Budapest

3529

89Bio Clinical Study Site, Miskolc

4032

89Bio Clinical Study Site, Debrecen

5600

89Bio Clinical Study Site, Békéscsaba

12203

89Bio Clinical Study Site, Albany

14021

89Bio Clinical Study Site, Prague

20110

89Bio Clinical Study Site, Manassas

27408

89Bio Clinical Study Site, Greensboro

28655

89Bio Clinical Study Site, Morganton

29435

89Bio Clinical Study Site, Summerville

30044

89Bio Clinical Study Site, Lawrenceville

32205

89Bio Clinical Study Site, Jacksonville

32825

89Bio Clinical Study Site, Orlando

33014

89Bio Clinical Study Site, Miami Lakes

33016

89Bio Clinical Study Site, Miami Lakes

33125

89Bio Clinical Study Site, Miami

33135

89Bio Clinical Study Site, Miami

33162

89Bio Clinical Study Site, North Miami Beach

33467

89Bio Clinical Study Site, Greenacres City

33606

89Bio Clinical Study Site, Tampa

33756

89Bio Clinical Study Site, Clearwater

37421

89Bio Clinical Study Site, Chattanooga

37660

89Bio Clinical Study Site, Kingsport

38654

89Bio Clinical Study Site, Olive Branch

40213

89Bio Clinical Study Site, Louisville

43303

89Bio Clinical Study Site, Marion

50266

89Bio Clinical Study Site, West Des Moines

60084

89Bio Clinical Study Site, Wauconda

62301

89Bio Clinical Study Site, Quincy

75204

89Bio Clinical Study Site, Dallas

76550

89Bio Clinical Study Site, Lampasas

77089

89Bio Clinical Study Site, Houston

77355

89Bio Clinical Study Site, Magnolia

77365

89Bio Clinical Study Site, Dallas

78705

89Bio Clinical Study Site, Austin

91942

89Bio Clinical Study Site, La Mesa

94158

89Bio Clinical Study Site, San Francisco

530 02

89Bio Clinical Study Site, Pardubice

100 00

89Bio Clinical Study Site, Prague

150 00

89Bio Clinical Study Site, Prague

158 00

89Bio Clinical Study Site, Prague

Unknown

89Bio Clinical Study Site, Baja

15-351

89Bio Clinical Study Site, Bialystok

15-879

89Bio Clinical Study Site, Bialystok

93-338

89Bio Clinical Study Site, Lodz

32-600

89Bio Clinical Study Site, Oświęcim

35-055

89Bio Clinical Study Site, Rzeszów

87-100

89Bio Clinical Study Site, Torun

Sponsors

Lead Sponsor

All Listed Sponsors
lead

89bio, Inc.

INDUSTRY